Redeye reviews the Sprint Bioscience case following a change of analyst and provides a more in-depth take on the company’s recent VADA deal. We believe upcoming triggers relating to Vps34 and VADA, in particular, bode well for the share price development. We adjusted our base case to SEK3.4 (SEK1.1).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.
www.redeye.se/

Attachments

Sprint Bioscience - New beginnings

© Modular Finance, source Nordic Press Releases